Yihui Ma1, Pengyu Zhang2, Yi Gao3, Huijie Fan3, Mingzhi Zhang3, Jingjing Wu3. 1. Department of Pathology, Henan Key Laboratory for Tumour Pathology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450002, Henan Province, P. R. China. 2. Department of Endocrinology, Cancer Research Institute, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450002, Henan Province, P. R. China. 3. Department of Oncology, Cancer Research Institute, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450002, Henan Province, P. R. China.
Abstract
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma with quite high mortality. PTEN/PI3K/AKT signal pathway is constitutively activated and plays an oncogenic role in most tumors including non-Hodgkin's lymphoma (NHL). Since rituximab used in chemotherapy has been proved to improve the survival of DLBCL patients, rituximab resistance is a common clinical challenge in the treatment of DLBCL. The aims of the present study are to determine the different levels of several important biomarkers of PTEN/PI3K/AKT pathway in DLBCL patients who are resistant or sensitive to rituximab treatment, and investigate the potential clinical application of these biomarkers. METHODS: 48 patients with DLBCL who were treated by rituximab-based chemotherapy were divided into 2 groups according to their reactions to rituximab. The expression of p-AKT, PTEN, and Ki-67 protein in 48 DLBCL tissues were detected using immunohistochemistry and analyzed for the clinical pathological significance and the resistance to rituximab. Meanwhile, PTEN gene deletion was detected also by FISH, and mutation of PIK3CA was performed by sequencing analysis. RESULTS: Activation of p-AKT in 12 of 48 (25.0%) and loss expression of PTEN in 15 of 48 (31.3%) DLBCL species were observed. P-AKT activation (P<0.05) and loss of PTEN expression (P<0.05) were significantly associative with high Ki-67 index. P-AKT and PTEN expression showed a significant negative correlation in all 48 DLBCL patients (r=-0.450, P<0.05), and the Spearman correlation coefficient in the resistant group (r=-0.769, P<0.05) was greater than in the sensitive group (r=-0.691, P<0.05). CONCLUSION: Regulation of PTEN/PI3K/AKT signal pathway participates in the progression of DLBCL, and may be involved in the development of the resistance to rituximab for some DLBCL patients.
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma with quite high mortality. PTEN/PI3K/AKT signal pathway is constitutively activated and plays an oncogenic role in most tumors including non-Hodgkin's lymphoma (NHL). Since rituximab used in chemotherapy has been proved to improve the survival of DLBCL patients, rituximab resistance is a common clinical challenge in the treatment of DLBCL. The aims of the present study are to determine the different levels of several important biomarkers of PTEN/PI3K/AKT pathway in DLBCL patients who are resistant or sensitive to rituximab treatment, and investigate the potential clinical application of these biomarkers. METHODS: 48 patients with DLBCL who were treated by rituximab-based chemotherapy were divided into 2 groups according to their reactions to rituximab. The expression of p-AKT, PTEN, and Ki-67 protein in 48 DLBCL tissues were detected using immunohistochemistry and analyzed for the clinical pathological significance and the resistance to rituximab. Meanwhile, PTEN gene deletion was detected also by FISH, and mutation of PIK3CA was performed by sequencing analysis. RESULTS: Activation of p-AKT in 12 of 48 (25.0%) and loss expression of PTEN in 15 of 48 (31.3%) DLBCL species were observed. P-AKT activation (P<0.05) and loss of PTEN expression (P<0.05) were significantly associative with high Ki-67 index. P-AKT and PTEN expression showed a significant negative correlation in all 48 DLBCL patients (r=-0.450, P<0.05), and the Spearman correlation coefficient in the resistant group (r=-0.769, P<0.05) was greater than in the sensitive group (r=-0.691, P<0.05). CONCLUSION: Regulation of PTEN/PI3K/AKT signal pathway participates in the progression of DLBCL, and may be involved in the development of the resistance to rituximab for some DLBCL patients.
Authors: Robert T Abbott; Sheryl Tripp; Sherrie L Perkins; Kojo S J Elenitoba-Johnson; Megan S Lim Journal: Mod Pathol Date: 2003-06 Impact factor: 7.842
Authors: Matthias Pfeifer; Michael Grau; Dido Lenze; Sören-Sebastian Wenzel; Annette Wolf; Brigitte Wollert-Wulf; Kerstin Dietze; Hendrik Nogai; Benjamin Storek; Hannelore Madle; Bernd Dörken; Martin Janz; Stephan Dirnhofer; Peter Lenz; Michael Hummel; Alexandar Tzankov; Georg Lenz Journal: Proc Natl Acad Sci U S A Date: 2013-07-09 Impact factor: 11.205
Authors: Hong Qin; Guowei Wei; Ippei Sakamaki; Zhenyuan Dong; Wesley A Cheng; D Lynne Smith; Feng Wen; Han Sun; Kunhwa Kim; Soungchul Cha; Laura Bover; Sattva S Neelapu; Larry W Kwak Journal: Clin Cancer Res Date: 2017-11-27 Impact factor: 12.531
Authors: Xiaoxiao Wang; Xin Cao; Ruifang Sun; Charlene Tang; Alexandar Tzankov; Jun Zhang; Ganiraju C Manyam; Min Xiao; Yi Miao; Kausar Jabbar; Xiaohong Tan; Yuyang Pang; Carlo Visco; Yan Xie; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Jane N Winter; Miguel A Piris; Shaoying Li; Roberto N Miranda; L Jeffrey Medeiros; Yong Li; Zijun Y Xu-Monette; Ken H Young Journal: Neoplasia Date: 2018-05-04 Impact factor: 5.715
Authors: Isha Kapoor; Yue Li; Arishya Sharma; Huayuan Zhu; Juraj Bodo; Wei Xu; Eric D Hsi; Brian T Hill; Alexandru Almasan Journal: Cell Death Dis Date: 2019-12-04 Impact factor: 8.469
Authors: Maria Bhatti; Thomas Ippolito; Cory Mavis; Juan Gu; Mitchell S Cairo; Megan S Lim; Francisco Hernandez-Ilizaliturri; Matthew J Barth Journal: Oncotarget Date: 2018-04-24
Authors: Jose Antonio Ma G Garrido; Krizelle Mae M Alcantara; Joshua Miguel C Danac; Fidel Emmanuel C Serrano; Eva Maria Cutiongco-de la Paz; Reynaldo L Garcia Journal: Cells Date: 2021-12-05 Impact factor: 6.600